前列腺癌中的神经内分泌细胞与不良结局相关:系统综述与荟萃分析
该系统综述与荟萃分析共纳入62项研究、7616例患者,评估四种神经内分泌标志物在前列腺腺癌中的染色阳性率及其与患者结局的关系。结果显示,嗜铬粒蛋白A(CgA)阳性率受报告标准影响,采用客观阈值可降低异质性;按客观标准CgA染色阳性的患者生化进展更快、前列腺癌特异性生存更差。
要点
- CgA pooled阳性率为41%,与NSE(39%)相近,高于突触素(31%)。
- 采用客观阈值后,CgA阳性率的异质性降低至26%。
- 按客观标准CgA阳性者生化进展风险增高(HR 1.98),前列腺癌特异性生存更差(HR 7.03)。
核心结论
- 腺癌中神经内分泌细胞报告阳性率的差异源于评分标准不一致。
- 当采用客观标准评估神经内分泌细胞染色时,可识别出临床结局较差的患者。
- 未来需研究确定可用于报告神经内分泌细胞染色的确切可量化阈值,以识别进展风险较高的患者。
研究设计与样本
- 系统综述与荟萃分析,检索医学数据库,纳入对腺癌标本进行CgA、NSE、突触素或CD56任一神经内分泌标志物染色的研究。
- 共分析62项研究、7616例患者,采用随机效应模型分析神经内分泌染色阳性率及其与患者结局的相关性,所有统计检验均为双侧。
主要发现
- CgA的合并阳性率为41%,与NSE的39%相近,高于突触素的31%。
- CgA染色阳性率显著受报告标准影响,采用客观阈值后阳性率变异降低至26%。
- CgA阳性率与肿瘤分级之间未发现相关性。
- 按客观标准CgA染色阳性的患者较阴性患者生化进展更快(HR 1.98,95%CI 1.49至2.65),前列腺癌特异性生存更差(HR 7.03,95%CI 2.55至19.39),即使在低危癌症患者中亦如此。
关键数值与推荐
- CgA合并阳性率41%,NSE 39%,突触素31%。
- 采用客观阈值后CgA阳性率变异降低至26%。
- CgA阳性(客观标准)与生化进展相关:HR 1.98(95%CI 1.49至2.65)。
- CgA阳性(客观标准)与前列腺癌特异性生存相关:HR 7.03(95%CI 2.55至19.39)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未来需研究确定可用于报告神经内分泌细胞染色的确切可量化阈值,以识别进展风险较高的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To perform a systematic review and meta-analysis of the literature to understand the variation in the reporting of neuroendocrine staining and determine the influence of reporting neuroendocrine staining at diagnosis on patient outcomes. METHODS: Medical databases were searched to identify studies in which adenocarcinoma specimens were stained with any of the following four neuroendocrine markers: chromogranin A (CgA), neuron-specific enolase (NSE), synaptophysin and CD56. The prevalence of neuroendocrine staining and correlation of the prevalence of neuroendocrine staining to patient outcomes were analysed using a random-effects model. All statistical tests were two-sided. RESULTS: Sixty-two studies spanning 7616 patients were analysed. The pooled prevalence for the most common marker, CgA (41%), was similar to that of NSE (39%) and higher than that of synaptophysin (31%). The prevalence of CgA staining was significantly influenced by reporting criteria, where objective thresholds reduced the variation in prevalence to 26%. No correlation was found between CgA prevalence and tumour grade. Patients positive for CgA staining using objective criteria had more rapid biochemical progression (hazard ratio [HR] 1.98, 95% confidence interval [CI] 1.49 to 2.65) and poorer prostate cancer-specific survival (HR 7.03, 95% CI 2.55 to 19.39) compared to negative patients, even among those with low-risk cancers. CONCLUSION: Discrepancies in the reported prevalence of neuroendocrine cells in adenocarcinoma are driven by the inconsistent scoring criteria. This study unequivocally demonstrates that when neuroendocrine cell staining is assessed with objective criteria it identifies patients with poor clinical outcomes. Future studies are needed to determine the exact quantifiable thresholds for use in reporting neuroendocrine cell staining to identify patients at higher risk of progression.
引用
- Kannan A, Clouston D, Frydenberg M, et al. Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta-analysis. BJU Int. 2021. PMID: 34784097. doi:10.1111/bju.15647
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。